BioSpace News Archive

Arrowhead Pharmaceuticals Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.

Albireo Pharma, Inc. today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.

Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET.

VectivBio Holding AG today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced it will host a conference call on Tuesday November 15 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the third quarter 2022, in addition to providing a business update.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on Wednesday, November 16, 2022, which includes a presentation beginning at 12:00 pm CT.

Oramed Pharmaceuticals Inc. today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (“T2D”) patients with non-alcoholic steatohepatitis (“NASH”) on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date 2022 financial results and provided a corporate update.

Prolacta Bioscience® announced the publication of a journal article that showed improved long-term neurodevelopmental outcomes in extremely premature infants who received Prolacta’s 100% human milk-based fortifiers as part of an Exclusive Human Milk Diet, compared with infants fed a cow milk-based diet in the neonatal intensive care unit.